Detalhe da pesquisa
1.
Value of Reducing Wait Times for Chimeric Antigen Receptor T-Cell Treatment: Evidence From Randomized Controlled Trial Data on Tisagenlecleucel for Diffuse Large B-Cell Lymphoma.
Value Health
; 25(8): 1344-1351, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35341689
2.
Indirect comparison of tisagenlecleucel and historical treatments for relapsed/refractory diffuse large B-cell lymphoma.
Blood Adv
; 6(8): 2536-2547, 2022 04 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-35030634
3.
Comparative efficacy of tisagenlecleucel and lisocabtagene maraleucel among adults with relapsed/refractory large B-cell lymphomas: an indirect treatment comparison.
Leuk Lymphoma
; 63(4): 845-854, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-34978255
4.
Indirect comparison of tisagenlecleucel and blinatumomab in pediatric relapsed/refractory acute lymphoblastic leukemia.
Blood Adv
; 5(23): 5387-5395, 2021 12 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-34597381
5.
Individualizing treatment targets for elderly patients with type 2 diabetes: factors influencing clinical decision making in the 24-week, randomized INTERVAL study.
Aging (Albany NY)
; 9(3): 769-777, 2017 03 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-28260692
6.
Long-term safety for patients with tisagenlecleucel-treated relapsed/refractory diffuse large B-cell lymphoma.
Blood Adv
; 6(16): 4816-4820, 2022 08 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-35687492